4D Molecular Therapeutics FDMT Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's change in deferred revenue?
- 4D Molecular Therapeutics (FDMT) reported change in deferred revenue of $1.38M in Q1 2026.
- How has 4D Molecular Therapeutics's change in deferred revenue changed year-over-year?
- 4D Molecular Therapeutics's change in deferred revenue increased by 9957.1% year-over-year, from -$14K to $1.38M.
- What is the long-term trend for 4D Molecular Therapeutics's change in deferred revenue?
- Over 3 years (2021 to 2025), 4D Molecular Therapeutics's change in deferred revenue has grown at a -76.0% compound annual growth rate (CAGR), from -$15.07M to -$209K.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.